Core Viewpoint - The company, Fuhong Hanlin (02696), has announced the completion of the first patient dosing in the United States for an international multicenter phase II clinical trial of HLX43, a PD-L1 targeted antibody-drug conjugate, in patients with advanced non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Details - The phase II clinical trial is designed to evaluate the efficacy and safety of HLX43 in patients with advanced NSCLC [1] - The study consists of two phases: the first phase focuses on dose exploration to select an appropriate dose for the second phase, which is a single-arm, multicenter phase II clinical study [1] - The primary objective of the study is to assess the clinical efficacy of HLX43 in advanced NSCLC, with the main endpoint being the objective response rate evaluated by a blinded independent review committee according to RECIST v1.1 criteria [1] Group 2: Market Context - As of the date of the announcement, there are no approved PD-L1 targeted antibody-drug conjugates available in the global market [1]
复宏汉霖：注射用HLX43(靶向PD-L1抗体偶联药物)用于治疗晚期非小细胞肺癌的国际多中心2期临床研究完成美国首例患者给药